Emerging in the arena of excess body fat treatment, retatrutide presents a different strategy. Different from many current medications, retatrutide functions as a double agonist, concurrently affecting both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) sensors. This concurrent engagement encourages various advantag